The Interplay Between Oxalate, Immunity and Infection

NCT04605055 | Withdrawn

• 1 other identifier: IRB-300005965
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study consists of having subjects, those with calcium oxalate kidney stones as well as healthy controls, consume low and oxalate enriched diets to investigate the role of oxalate on crystalluria (the presence of crystals in urine), immunity and infection.

Conditions

Kidney Stone

Keywords

Oxalate

Outcome Measures

Primary Outcomes (5)

• Urinary Oxalate

  Twenty-four hour urinary oxalate will be reported as mg/day

  Change between Baseline and Diets at 4 days

• Crystalluria

  Twenty-four hour crystalluria will be reported as particles/ml

  Change between Baseline and Diets at 4 days

• Monocyte Cellular Bioenergetics

  Cellular bioenergetics will be reported as oxygen consumption rate

  Change between Baseline and Diets at 4 days

• Monocyte Mitochondrial Complex Activity

  Monocyte mitochondrial complex activity will be reported as oxygen consumption rate

  Change between Baseline and Diets at 4 days

• Monocyte Transcriptomics

  Monocyte transcriptomics will be reported as gene expression (mRNA levels)

  Change between Baseline and Diets at 4 days

Study Arms (2)

Low Oxalate Diet Followed by High Oxalate Diet

EXPERIMENTAL

Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.

Dietary Supplement: Low Oxalate Diet; Dietary Supplement: High Oxalate Diet

High Oxalate Diet Followed by Low Oxalate Diet

EXPERIMENTAL

Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.

Dietary Supplement: Low Oxalate Diet; Dietary Supplement: High Oxalate Diet

Interventions

Low Oxalate Diet DIETARY_SUPPLEMENT

Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.

High Oxalate Diet Followed by Low Oxalate Diet; Low Oxalate Diet Followed by High Oxalate Diet

High Oxalate Diet DIETARY_SUPPLEMENT

Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.

High Oxalate Diet Followed by Low Oxalate Diet; Low Oxalate Diet Followed by High Oxalate Diet

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to provide informed consent
• Body Mass Index (BMI) between 20-30 kg/m2
• Non tobacco users or not pregnant/breast feeding/nursing
• Normal fasting blood comprehensive metabolic panel, complete blood count, C-reactive protein, and urinalysis. Must accurately collect two 24-hour urine collections within 20% of appropriate ratio of creatinine (mg)/body weight (kg) for gender
• Healthy subjects: No history of calcium oxalate kidney stones (CaOx KS) or other medical conditions
• Patients with CaOx KS: Recent stone composition greater than 50% CaOx; no uric acid or struvite stone content must be present. Must be first time or recurrent CaOx stone former (last stone event within the past 3 years)
• Willing to not consume supplements (i.e. vitamins, Ca (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, and probiotics) for 2 weeks before the study and during the study
• Willing to abstain from vigorous exercise during the study as this may compromise immune function.
• Willing to consume diets provided only by the University of Alabama Center for Clinical and Translational Science Bionutrition Core. No food allergies or intolerance to any of the foods on the study menus.
• Willing to accurately collect 24-hour urine samples, and to have blood drawn throughout the study.
• If on medications for kidney stone prevention (e.g. thiazides, citrate supplementation excluding calcium citrate), patients must be on a stable dose regimen for at least 8 weeks prior to and during screening, with no changes in dosing anticipated during the study. Patients should not take allopurinol for 2 weeks prior to screening since allopurinol has anti-oxidant properties.

You may not qualify if:

• Inability to sign and read the informed consent
• Any medical, psychiatric, or social conditions that would prohibit participants from abiding to the study requirements
• BMI greater than 30 kg/m2 or less than 20 kg/m2
• Tobacco users or pregnant or breast feeding/nursing women
• Abnormal fasting blood comprehensive metabolic panel, complete blood count, C-reactive protein, and urinalysis. Inaccurate 24-hour urine collections.
• Healthy subjects: Taking medications or dietary supplements. History of kidney stones or any medical condition that could influence absorption or excretion of oxalate.
• Active illness including COVID-19, flu, common cold, fever, diarrhea, urinary tract infections or other infections 14 days before the study and throughout the study.
• Active disease including diabetes, gout, hypertension, primary hyperoxaluria, nephrotic syndrome, enteric hyperoxaluria, renal tubular acidosis, primary hyperparathyroidism, liver disease, autoimmune disorder, neurogenic bladder, urinary diversion, and bariatric surgery.
• Active malignancy or treatment for malignancy within 12 months prior to screening.

Sponsors & Collaborators

• University of Alabama at Birmingham: lead

MeSH Terms

Conditions

Kidney Calculi

Condition Hierarchy (Ancestors)

Nephrolithiasis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urolithiasis; Urinary Calculi; Male Urogenital Diseases; Calculi; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Tanecia Mitchell, PhD

  University of Alabama at Birmingham

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 12, 2020
• First Posted: October 27, 2020
• Study Start: June 1, 2025
• Primary Completion (Estimated): October 30, 2027
• Study Completion (Estimated): December 30, 2027
• Last Updated: June 10, 2025

Record last verified: 2025-06